Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/jhg.2010.153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Axon guidance in central nervous system regeneration.
Dev Cell
December 2024
Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA 94303, USA. Electronic address:
Critical molecular pathways promote central nervous system (CNS) axon regeneration, but can axons be guided to their correct targets in adulthood? In this issue of Developmental Cell, Delpech et al. show that axonal guidance cues in the CNS can be manipulated to enhance anatomic and functional recovery.
View Article and Find Full Text PDFFinerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
JAMA Cardiol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Article Synopsis
- The study investigates the safety and efficacy of finerenone in treating heart failure, focusing on differences between men and women.
- Conducted as part of the FINEARTS-HF trial, it included over 6000 participants aged 40 and older across multiple countries.
- Results show that finerenone significantly reduces the risk of combined cardiovascular death and heart failure events in both sexes, with women experiencing slightly better outcomes on average.
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
JAMA Cardiol
January 2025
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved outcomes for heart failure patients in the FINEARTS-HF trial but led to elevated serum potassium levels.
- The study aimed to analyze the frequency of abnormal serum potassium levels (<3.5 mmol/L and >5.5 mmol/L) and the impact of finerenone treatment compared to placebo on patient outcomes.
- Results showed that participants taking finerenone experienced significantly higher potassium levels over time, with increased risk of levels >5.5 mmol/L and reduced risk of levels <3.5 mmol/L, indicating a notable effect of the drug on potassium regulation.
A Human Touch: Hominid-Specific LRRC37B Regulates Axon Initial Segment Excitability.
Epilepsy Curr
May 2024
Division of Neurology, Department of Pediatrics, Epilepsy NeuroGenetics Initiative, The Children's Hospital of Philadelphia Department of Neurology, Department of Neuroscience, The Perelman School of Medicine at The University of Pennsylvania.
Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.
JAMA Cardiol
October 2024
Ascension St Vincent Heart Center, Indianapolis, Indiana.
Article Synopsis
- About 40% of heart failure patients eligible for cardiac resynchronization therapy (CRT) do not respond or cannot be treated, highlighting the need for alternative options.
- The SOLVE-CRT study evaluated the safety and effectiveness of a new leadless left ventricular pacing system for high-risk patients or those who had unsuccessful CRT using conventional methods.
- The study involved 183 participants, primarily older males, and was stopped early due to positive results showing improvements in safety and a decrease in heart chamber size.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!